The high recurrence rates of Clostridioides difficile infection highlight the need for novel agents with unique mechanisms of action for treating the infection.
Ellie J.C. Goldstein, MD, FIDSA, FSHEA
Advertisement
Articles by Ellie J.C. Goldstein, MD, FIDSA, FSHEA
Advertisement
Latest Updated Articles
- Investigational Treatments for Clostridioides difficile Infection
October 10th 2019
Advertisement
Advertisement
Trending on Contagion Live
1
Review of Cefepime and Zidebactam: A Novel Antibiotic Approved to Treat Complicated Urinary Tract Infections
2
FDA Expands Merck Pneumococcal Vaccine Indication to Include At-Risk Children and Adolescents
3
mRNA-based Influenza Vaccine Advances Against HHS Resistance
4
Vaccine for Lassa Fever Succeeds in First-in-Human Trial
5